ReviewNeuropathology and applied neurobiology2012
Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
Review in Neuropathology and applied neurobiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Clinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data.Journal of neuro-oncology · 2018Pooled it
- PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma.Journal of neuro-oncology · 2026Article
- Genetic feature selection algorithm as an efficient glioma grade classifier.Scientific reports · 2025Article
- Key genes altered in glioblastoma based on bioinformatics (Review).Oncology letters · 2025Review
- Extra-temporal pediatric low-grade gliomas and epilepsy.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Review
- Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics.Cancer cell international · 2023Review
- Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable for Nanotherapeutic Delivery.Pharmaceutics · 2023Article
- Phenotype and Neuronal Cytotoxic Function of Glioblastoma Extracellular Vesicles.Biomedicines · 2022Article
- Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies.Inflammopharmacology · 2021Review
- Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis.Neuro-oncology · 2021Article
- Review
- miRNA-21 may serve as a promising noninvasive marker of glioma with a high diagnostic performance: a pooled analysis of 997 patients.Therapeutic advances in medical oncology · 2021Article
- Brucine inhibits proliferation of glioblastoma cells by targeting the G-quadruplexes in the c-Myb promoter.Journal of Cancer · 2021Article
- Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.BMC cancer · 2020Article
- Codependency of Metabolism and Epigenetics Drives Cancer Progression: A Review.Acta histochemica et cytochemica · 2020Review
- Development of a Microfluidic Culture Paradigm for Ex Vivo Maintenance of Human Glioblastoma Tissue: A New Glioblastoma Model?Translational oncology · 2020Article
- SH3KBP1 Promotes Glioblastoma Tumorigenesis by Activating EGFR Signaling.Frontiers in oncology · 2020Article
- Comparative proteogenomic characterization of glioblastoma.CNS oncology · 2019Article
- Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity.Oncology letters · 2019Article
- Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR.JCI insight · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The classification of malignant gliomas is moving from a morphology-based guide to a system built on molecular criteria. The development of a genomic landscape for gliomas and a better understanding of its functional consequences have led to the development of internally consistent molecular classifiers. However, development of a biologically insightful classification to guide therapy is still a work in progress. Response to targeted treatments is based not only on the presence of drugable targets, but rather on the molecular circuitry of the cells. Further, tumours are heterogeneous and change and adapt in response to drugs. Therefore, the challenge of developing molecular classifiers that provide meaningful ways to stratify patients for therapy remains a major challenge for the field. In this review, we examine the potential role of MGMT methylation, IDH1/2 mutations, 1p/19q deletions, aberrant epidermal growth factor receptor and PI3K pathways, abnormal p53/Rb pathways, cancer stem-cell markers and microRNAs as prognostic and predictive molecular markers in the setting of adult high-grade gliomas and we outline the clinically relevant subtypes of glioblastoma with genomic, transcriptomic and proteomic integrated analyses. Furthermore, we describe how these advances, especially in epidermal growth factor receptor/PI3K/mTOR signalling pathway, affect our approaches towards targeted therapy, raising new challenges and identifying new leads.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.